The Three 'Cs' of Biomarker Development
This article was originally published in Scrip
Executive Summary
Dr Elizabeth Foot, CEO of London Genetics, argues that biomarker-driven drug development is the only way for biopharmaceutical companies to survive the changing face of healthcare, and outlines the three essentials for the successful development of targeted drugs. Comments are based on a paper given at the BioStorage Technologies first annual Global Sample Management Benchmarking Symposium, Germany, September 15 2010.